Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations (Q35129194)

6 August 2017

1 reference

title

Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations (English)

1 reference

6 August 2017

main subject

anti-retroviral agent

0 references

0 references

2

Ingrid Uhnoo

1 reference

6 August 2017

10

Anders Sönnerborg

1 reference

6 August 2017

6

Magnus Gisslén

1 reference

6 August 2017

4

Göran Bratt

1 reference

6 August 2017

Eric Sandström

1

1 reference

6 August 2017

Jane Ahlqvist-Rastad

3

1 reference

6 August 2017

Torsten Berglund

5

1 reference

6 August 2017

Stefan Lindbäck

7

1 reference

6 August 2017

Linda Morfeldt

8

1 reference

6 August 2017

Lars Ståhle

9

1 reference

6 August 2017

Swedish Consensus Group

11

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

35

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

155-167

1 reference

Factors affecting adherence to antiretroviral therapy

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Final analysis of the Trilège induction-maintenance trial: results at 18 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 x 10(6)/l, AIDS, and death from AIDS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Immune restoration and CD4+ T-cell function with antiretroviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Position paper on therapeutic drug monitoring of antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540310006395

10.1080/00365540310006395

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference